Stock Screener App

Frei -

Installieren

21.13

12.10% -2.91

after-market

Handel nachbörslich: 21.02 -0.11 -0.52%

Oruka Therapeutics Inc (ORKA)

Überblick Nachrichten Preisverlauf Forum Prognose

Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten

Oruka Therapeutics adjusts financials post-merger By Investing.com - Investing.com Canada

JANUS HENDERSON GROUP PLC Acquires New Stake in Oruka Therapeuti - GuruFocus.com

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Oruka Therapeutics Raises $475M, Accelerates Clinical Timeline for Key Drug Programs | ORKA Stock News - StockTitan

Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan

Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha

Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada

Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks

Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga

Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada

Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian

Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan

Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks

Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World

Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia

Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World

Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga

‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online

Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald

Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha

‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World

Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World

Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily

‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer

Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Leerink Partners starts drug developer Oruka with 'outperform' - XM

Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga

Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter

Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World

Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks

FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT

Oruka to advance psoriasis programs into clinic next year - BioWorld Online

Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK

Biotech firm enters $200M agreement - The Business Journals

Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada

Oruka Therapeutics sets clinical trial dates for skin disease drugs - Investing.com

Oruka Therapeutics secures $200 million in PIPE financing - Investing.com

Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewswire

Oruka Therapeutics Announces Accelerated Clinical Timelines - GlobeNewswire

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 - StockTitan

Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wedbush - Defense World

Arca Biopharma, Oruka Therapeutics merger complete - Boulder Daily Camera

Oruka Therapeutics (NASDAQ:ORKA) Receives New Coverage from Analysts at Wedbush - Defense World

Oruka announces closing of merger with ARCA Biopharma - TipRanks

ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView

Oruka Therapeutics Announces Closing of Merger with ARCA - GlobeNewswire

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million - StockTitan

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split - ForexTV.com

SMMT

$18.98

3.66%

INCY

$76.97

1.45%

MRNA

$39.51

7.22%

UTHR

$359.21

1.11%

BGNE

$187.69

0.81%

BNTX

$101.87

2.16%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters